Skip to main content

Patricia A. Thompson, Ph.D.

Professor, Physiology
Dr. Patricia Thompson, PhD
pcarino@arizona.edu

My laboratory focuses on  developing and testing chemopreventive strategies targeting early mechanisms of tumorigenesis and translating discoveries in the lab into early phase chemoprevention clinical trials. A major area of interest in the laboratory is on immune and inflammatory pathways in cancer, utilizing immune modulating agents like nonsteroidal anti-inflammatory drugs, statins, and anti-RANK ligand antibodies for cancer prevention. I currently co-lead the University of Arizona Chemoprevention Clinical Trials Network at the Arizona Cancer Center.  The lab is currently investigating pharmacologic mimics of fasting for effects on tumor growth and as adjuncts for endocrine therapy in breast and prostate tumor models.  

Publication Highlights
Thompson, P. A., C.-H. Hsu, S. Green, A. T. Stopeck, K. Johnson, D. S. Alberts and H.-H. S. Chow (2010). Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial. Cancer Prevention Research 3(1): 101-107. PMID: 20051377 PMCID: PMC3993089.
Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu C-H, Chow H-HS, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P. Design and Baseline Characteristics of Participants in Phase III Randomized Trial of Celecoxib and Selenium for Colorectal Adenoma Prevention. Cancer Prevention Research. 2012;5(12):1381-1393.
Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu C-H, Chow HHS, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez ME, Alberts DS, Lance P. Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. J Natl Cancer Inst. 2016;108(12).
Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu C-H, Chow SHH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J Natl Cancer Inst 2016;108(12):
Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017; 165(1):97-107 PMID: 28560655 PMCID: PMC5571834.
Martinez JA, Yang J, Wertheim BC, Roe DJ, Schriewer A, Lance P, Alberts DS, Hammock BD, Thompson PA. Celecoxib use and circulating oxylipins in a colon polyp prevention trial. PLoS One. 2018 Apr 26;13(4):e0196398.
Thompson PA, Huang C, Yang J, Wertheim BC, Roe D, Zhang X, Ding J, Chalasani P, Preece C, Martinez J, Chow HS, Stopeck AT. Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors. Clin Cancer Res. 2021 Oct 15;27(20):5660-5668. PMCID: PMC8793363.
Martinez JA, Wertheim BC, Roe DJ, Chalasani P, Cohen J, Baer L, Chow HS, Stopeck AT, Thompson PA. Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer. Breast Cancer Res Treat. 2022 Feb;192(1):113-122.

Degrees

  • 1993 PhD - Immunology & Microbiology, University of Texas Health Science Center, San Antonio, TX
  • 1986 BS - Biology, Angelo State University, San Angelo, TX
  • 1993 Fellowship - Virology/Immunology, Southwest Research Foundation, San Antonio, TX
  • 1994 Fellowship - Molecular Immunology, University of Texas Health Science Center, San Antonio, TX
  • 1996 Fellowship - Molecular Epidemiology, National Center for Toxicology Research, Jefferson Arkansas